276?1253660878
New Treatments in Development User Group
Ketamine in Clinical Study for Bipolar Depression
About This Group:

This group is to discuss new treatments in development to have a better understanding of the future of recovery.

Founded by ILADVOCATE on September 22, 2009
41 members
Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Ketamine in Clinical Study for Bipolar Depression

http://www.nytimes.com/2010/08/10/health/10depress.html

"Anesthetic Said to Aid Depression"
"A new study suggests that a 50-year-old drug commonly used as an anesthetic for humans and animals" —
"may deliver almost instant relief in some of the most troublesome cases of bipolar depression.
It has been known for several years that small doses of the drug, ketamine, can relieve major depression. But this study, done by researchers at the National Institute of Mental Health, is the first to demonstrate efficacy in patients with treatment-resistant bipolar depression.
Indeed, the researchers said, the effect on this group appeared to be even stronger. Although the study was small, with just 18 patients, it was conducted under the highest standards for a drug study: it was randomized, placebo-controlled and double-blinded.
In bipolar disorder, sometimes called manic-depressive illness, patients cycle between periods of elation and severe depression, and the depressive phase carries a high risk of suicide. It is commonly treated with mood stabilizers, including lithium, anticonvulsants and some antipsychotics, often in complex combinations.
Both mania and depression usually improve on these drugs. But when the depression remains, it is notoriously difficult to treat, so a fast-acting medicine with lasting effects would have obvious advantages. Ketamine probably acts by limiting the action of one type of brain receptor that moves nerve signals between neurons."
2 Comments
Blank
1042487_tn?1275283499
It must be the case for most NDMA receptor antagonists... Even with the co-agonist glycine.
Blank
585414_tn?1288944902
Yes I am somewhat familiar with that. For example Namenda which is used to treat dementia is in clinical study as a mood stabilizer and to treat tardive dyskinesia. However as those medications specifically effect those receptors by mitigating their activity they work in an opposite manner to glycine and the NMDA receptor modulates. For that reason although my neurologist considered it I was not allowed to take Namenda for its usage on tardive because it would act against the glycine and make it less effective as they work in an opposite manner. The glutamate receptors are new as regards a specific clinical understanding and depending on the specific effect as regards treatment, medications that both mitigate their activity as is discussed in the article and enhance their activity (such as glycine) are being studied and as is always true treatments are being studied for further uses than they were originally developed for.
Blank
Recent Activity
585414_tn?1288944902
Blank
ILADVOCATE empowered and advocating fo... Comment
Sep 01
585414_tn?1288944902
Blank
ILADVOCATE commented on ILADVOCATE's status
Aug 07
387767_tn?1345875627
Blank
Cindee56 Crying Comment
Aug 02
MedHelp Health Answers